AstraZeneca Pharma India Limited has informed the Exchange regarding a press release dated May 26, 2026, titled "AstraZeneca Pharma India Limited marks consistent 33% growth as the Company announces its annual results for FY 2025-2026".
ASTRAZEN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 4.5 pts less than Nifty Microcap 250 and 4.7 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
AstraZeneca Pharma India reported strong full-year results for FY 2025-26 ending March 31, 2026. Total revenue from operations reached INR 22,755.8 Mn, marking a consistent 33% year-on-year growth. Profit after tax stood at INR 1,875.2 Mn with profit before tax at INR 2,574.5 Mn. The company received 11 regulatory approvals during the year across key therapy areas including Oncology (INR 16,100.9 Mn revenue), Biopharmaceuticals (INR 5,243.2 Mn), and Rare Disease (INR 214.6 Mn). Key approvals included Durvalumab for endometrial cancer and liver cancer, Eculizumab for rare diseases, and Osimertinib for NSCLC. The company celebrated 45 years in India and received multiple industry awards.
The 33% revenue growth demonstrates strong business momentum and validates the company's science-led portfolio strategy. Investors can expect positive sentiment given the consistent growth across therapy areas and the robust regulatory approval pipeline, though the high base effect may moderate future growth rates.